BRNS — Barinthus Biotherapeutics Share Price
0.000.00%
Last trade - 00:00- $109.18m
- -$20.61m
- $0.80m
- 39
- 22
- 31
- 21
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.6 | ||
| Price to Tang. Book | 0.76 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 308.21 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -42.51% | ||
| Return on Equity | -34.88% | ||
| Operating Margin | -23755.69% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.85 | 4.82 | 0.27 | 44.7 | 0.8 | 1 | 1 | -41.49% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Barinthus Biotherapeutics plc, formerly Vaccitech plc, is a clinical-stage biopharmaceutical company. It is focused on developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its four platform technologies include ChAdOx, MVA, SNAP-TI, and SNAP-CI. It is advancing a pipeline of five product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer, and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- March 22nd, 2021
- Public Since
- April 30th, 2021
- No. of Shareholders
- 70
- No. of Employees
- 130
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 77,986,114
- Address
- The Schrdinger Building, DIDCOT, OX11 0DF
- Web
- https://www.barinthusbio.com/
- Phone
- +44 1865818808
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for BRNS
Q3 2024 Barinthus Biotherapeutics PLC Earnings Release
Similar to BRNS
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Barinthus Biotherapeutics share price?
As of Today at 19:32 UTC, shares in Barinthus Biotherapeutics are trading at $1.32. This share price information is delayed by 15 minutes.
How has the Barinthus Biotherapeutics share price performed this year?
Shares in Barinthus Biotherapeutics last closed at $1.32 and the price had moved by -42.36% over the past 365 days. In terms of relative price strength the Barinthus Biotherapeutics share price has underperformed the S&P500 Index by -54.13% over the past year.
What are the analyst and broker recommendations for Barinthus Biotherapeutics?
The overall consensus recommendation for Barinthus Biotherapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Barinthus Biotherapeutics dividend yield?
Barinthus Biotherapeutics does not currently pay a dividend.
Does Barinthus Biotherapeutics pay a dividend?
Barinthus Biotherapeutics does not currently pay a dividend.
When does Barinthus Biotherapeutics next pay dividends?
Barinthus Biotherapeutics does not currently pay a dividend.
How do I buy Barinthus Biotherapeutics shares?
To buy shares in Barinthus Biotherapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Barinthus Biotherapeutics?
As of the previous close price of $1.32, shares in Barinthus Biotherapeutics had a market capitalisation of $102.94m.
Where are Barinthus Biotherapeutics shares listed?
Here are the trading details for Barinthus Biotherapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: BRNS
What kind of share is Barinthus Biotherapeutics?
Based on an overall assessment of its quality, value and momentum Barinthus Biotherapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Barinthus Biotherapeutics share price forecast for 2024?
The analyst consensus target price for shares in Barinthus Biotherapeutics is $5.80. That is 339.39% above the last closing price of $1.32.
Analysts covering Barinthus Biotherapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.66 for the next financial year.
What is the trend in the Barinthus Biotherapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Barinthus Biotherapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -65.16%.
As of the last closing price of $1.32, shares in Barinthus Biotherapeutics were trading -52.73% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Barinthus Biotherapeutics PE Ratio?
The Barinthus Biotherapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Barinthus Biotherapeutics?
We do not have data on Barinthus Biotherapeutics' directors